Results 121 to 130 of about 25,505 (239)

Pathogenic Huntingtin aggregates alter actin organization and cellular stiffness resulting in stalled clathrin-mediated endocytosis

eLife
Aggregation of mutant forms of Huntingtin is the underlying feature of neurodegeneration observed in Huntington’s disorder. In addition to neurons, cellular processes in non-neuronal cell types are also shown to be affected.
Surya Bansi Singh, Shatruhan Singh Rajput, Aditya Sharma, Sujal Kataria, Priyanka Dutta, Vaishnavi Ananthanarayanan, Amitabha Nandi, Shivprasad Patil, Amitabha Majumdar, Deepa Subramanyam   +9 more
doaj   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

ROS-Specific Huntingtin Interactions: Huntingtin pulldown of PARylated proteins

, 2019
<p>Huntingtin co-immunoprecipitation of proteins modified by poly ADP ribose.</p>This work is funded by the HDSA Berman/Topper HD Career Development ...
Maiuri, Tamara, Truant, Ray, Truant, Ray (5336200), Maiuri, Tamara (5336197)   +3 more
core   +1 more source

Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin [PDF]

, 2015
Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion.
Thompson, L. M., R Albay, J Overman, Potkin, K. T., R. Albay, W E Bunney, W. Dai, A. Demuro, Bunney, W. E., M. A. Digman, Albay, R, W. Chiu, Digman, MA, Overman, J., Macciardi, F., Glabe, C, Dai, W., S. G. Potkin, Thompson, LM, Tan, Z, Parker, I., C. Glabe, Overman, J, Demuro, A, Parker, I, W. E. Bunney, J. D. Long, van Erp, Theo G.M., Hatami, A, J. Overman, Potkin, Steven G., J. S. Paulsen, Chiu, W., van Erp, TGM, Albay, R., K. T. Potkin, Tan, Z., L. M. Thompson, Z Tan, J D Long, T G M van Erp, W Chiu, Digman, M. A., Long, J. D., S Ling, Paulsen, JS, Ling, S, J M Ringman, S G Potkin, S. Ling, Ringman, JM, Sontag, EM, A. Hatami, Bunney, WE, Demuro, A., Hatami, A., Ringman, J. M., C Glabe, Glabe, Charles G., Z. Tan, L M Thompson, E M Sontag, Macciardi, F, I. Parker, I Parker, Chiu, W, Sontag, Emily M., Dai, W, Long, JD, J S Paulsen, Potkin, KT, K T Potkin, M A Digman, Potkin, SG, J. M. Ringman, Ling, S., W Dai, A Demuro, Paulsen, J. S., E. M. Sontag, F. Macciardi, A Hatami, T. G. M. van Erp, F Macciardi   +83 more
core   +1 more source

The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor

BMC Neuroscience, 2002
Background Huntington's disease (HD) pathogenesis is due to an expanded polyglutamine tract in huntingtin, but the specificity of neuronal loss compared with other polyglutamine disorders also implies a role for the protein's unknown inherent function ...
Gusella James F, Takano Hiroki
doaj   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, Volume 41, Issue 6, Page 1492-1501, June 2026.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Taking a Break From Huntingtin [PDF]

Molecular Therapy - Nucleic Acids, 2012
Three groups have forged an important collaboration to test the utility of antisense oligonucleotides (ASOs) as a therapeutic modality for the treatment of Huntington's disease (HD), a fatal neurodegenerative disease manifesting in ~75,000 individuals in the United States and Europe alone.1 HD is one of a group of dominantly inherited neurodegenerative
openaire   +4 more sources

Huntingtin intrabody and nanobody literature review 10th January 2018

, 2018
Huntingtin structure-function open lab notebook project. To kick off the new year, I have been doing some reading on huntingtin intrabodies and nanobodies and have written this up into an informal literature review.
Harding, Rachel (4928305), Harding, Rachel   +1 more
core   +1 more source

Cilia in Nervous System Development, Function, and Disease

MedComm – Future Medicine, Volume 5, Issue 2, June 2026.
Cilia are evolutionarily conserved organelles that function as essential sensory and motility platforms in the nervous system. This review outlines key cilia‐dependent signaling pathways and their roles in neural development and function. Furthermore, it highlights how ciliary dysfunction can lead to a variety of neurological disorders, known as ...
Qingchao Li, Anqi Zhang, Ting Song
wiley   +1 more source

Huntingtin construct design for BioID 2018/04/02

, 2018
Huntingtin structure-function open lab notebook project. Huntingtin construct design for BioID 2018/04/02.
Arrowsmith, Cheryl (4928326), Edwards, Aled (4929298), Harding, Rachel (4928305), Harding, Rachel, Arrowsmith, Cheryl, Edwards, Aled   +5 more
core   +1 more source